Symbol | Exchange | Currency |
|---|
Investing.com - Abeona Therapeutics (NASDAQ: ABEO) reported first quarter EPS of $-0.5400, in line with the analyst estimate of $-0.5400. Revenue for the quarter came in at $0.00...
Abeona Therapeutics Inc. (Nasdaq: NASDAQ:ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its...
Investing.com - Abeona Therapeutics (NASDAQ: ABEO) reported first quarter EPS of $1.5300, $2.28 better than the analyst estimate of $-0.7500. Revenue for the quarter came in at $2M...
Biotech stocks offer investors a clear risk/reward proposition Investors should look at the company’s clinical focus and its pipeline Small-cap biotech stocks are among the...
Kodiak Sciences (NASDAQ:KOD) Inc. KOD announced that it has completed enrollment in the pivotal phase IIb/III DAZZLE study, which is evaluating its lead pipeline candidate KSI-301...
1. Amyris (NASDAQ:AMRS) popped on Monday with good volume, gaining 81 cents, or 30%, to 3.49, after reaching a session high of 3.70, on 6.4 million shares traded. It broke out...
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is EB-101, an autologous, engineered cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB). Its development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with unmet medical needs. The Company’s next generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility produced EB-101 for the pivotal Phase III VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. EB-101 is an autologous, engineered cell therapy in which a functioning COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) using a retrovirus.
| Average | 22.6667 (+621.8694% Upside) |
| High | 38.0000 |
| Low | 10.0000 |
| Price | 3.1400 |
| No. of Analysts | 3 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Buy | Sell |
| Technical Indicators | Buy | Strong Sell | Strong Sell | Buy | Strong Sell |
| Summary | Neutral | Strong Sell | Strong Sell | Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.70 | 7.84 | 7.54 | +0.16 | +2.12% | 43.11M | NYSE | |||
| 34.11 | 34.20 | 33.39 | +0.47 | +1.40% | 3.12M | NASDAQ | |||
| 0.637 | 0.665 | 0.625 | -0.013 | -2.00% | 6.46M | NASDAQ | |||
| 14.48 | 14.73 | 14.35 | 0.00 | 0.00% | 10.29M | NYSE | |||
| 59.00 | 60.40 | 58.97 | -0.30 | -0.51% | 10.09M | NYSE | |||
| 126.08 | 126.40 | 120.63 | +7.41 | +6.24% | 3.04M | NASDAQ | |||
| 166.15 | 170.00 | 159.55 | +7.27 | +4.58% | 2.10M | NASDAQ | |||
| 4.71 | 4.87 | 4.70 | -0.07 | -1.46% | 7.30M | NYSE | |||
| 2.38 | 2.39 | 2.32 | +0.020 | +0.85% | 1.65M | NASDAQ | |||
| 52.07 | 52.10 | 51.93 | +0.14 | +0.27% | 497.14K | NASDAQ | |||
| 2.64 | 2.85 | 2.62 | -0.200 | -7.04% | 1.35M | NASDAQ | |||
| 67.25 | 67.90 | 66.11 | +0.12 | +0.18% | 213.64K | NYSE | |||
| 13.83 | 14.18 | 13.71 | +0.07 | +0.51% | 1.41M | OTC Markets | |||
| 8.25 | 8.48 | 8.20 | -0.17 | -2.02% | 353.56K | NASDAQ | |||
| 1.37 | 1.42 | 1.33 | -0.020 | -1.44% | 149.95K | NASDAQ |